Objectives: We estimated the diagnostic accuracy of T2Candida, with blood culture (BC) as the gold standard, and compared turnaround time between these two techniques in order to investigate the potential role of T2Candida in the management of empirical antifungal treatment (EAT).
Introduction
Management of candidaemia is challenging for several reasons. First, prompt diagnosis is difficult as the gold-standard microbiological test, blood culture (BC), has low sensitivity and long turnaround time. 1 The poor sensitivity of BCs often means that appropriate antifungal treatment in patients with candidaemia is started late. Such delay is associated with increased mortality in several settings, from ICUs to internal medicine wards. [2] [3] [4] Thus, in patients with recognized risk factors for candidaemia who develop severe sepsis or septic shock, an empirical antimicrobial regimen that includes antifungals is recommended. [5] [6] [7] However, this approach may result in over-prescribing of antifungals with detrimental effects in terms of selective pressure with a shift to resistant Candida species, emergence of resistance and increased costs. 8, 9 T2Candida is a novel nanodiagnostic panel that uses T2 magnetic resonance (T2MR) and a dedicated instrument (T2Dx Instrument) to detect Candida directly in whole blood samples. 10 The panel detects the five most common pathogenic Candida species (Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei). T2Candida has proven to be efficient in identifying candidaemia to the species level in just 3 to 5 h, with an estimated sensitivity and specificity of 91.1% and 99.4%, respectively. 11 A decision-tree model study has estimated that hospitals may observe lower candidaemia-related inpatient costs and mortality using T2Candida versus BCs, with a 47.6% decrease in management budget and averting 60.6% of candidaemia-related mortality. 12 However, the use of T2Candida in real life, testing clinical samples from patients at high risk of candidaemia, and its potential impact on the management of empirical antifungal treatment (EAT), has scarcely been investigated. Recently, a multicentre study from Spain has shown that in patients at high risk of invasive Candida infection a positive T2Candida result is predictive of poor outcome. We performed a single-centre prospective observational study to estimate the diagnostic accuracy of T2Candida with BC as gold standard and to compare turnaround time between these two techniques in a group of patients with severe sepsis or septic shock and multiple risk factors for candidaemia.
Patients and methods

Study design, setting and population
This prospective observational study was carried out at the Sant'OrsolaMalpighi Hospital, a 1450 bed tertiary-care university hospital in Bologna, Northern Italy, from September 2016 to June 2017.
Patients receiving no palliative care for a terminal condition who presented all of the following criteria were included: (i) adult (18 years); (ii) severe sepsis or septic shock; 14 (iii) 2 risk factors for candidaemia among those listed in Table 1 ; 7 and (iv) initiation of EAT after drawing BCs.
Patients were screened for inclusion on the day of EAT initiation by infectious disease consultants (IDCs) during the daily activities; in those suited for enrolment, a blood sample for the T2Candida test was requested within 12 h of BCs. Results of T2Candida were not reported to physicians. Performance of BCs and initiation and duration of EAT were at the discretion of attending physicians and were not dictated by a study protocol. Patients were included only once.
Duration of EAT was defined as the number of consecutive days during which the patient received an antifungal for the suspicion of candidaemia pending microbiological test results.
Outcomes were assessed on day 90 after EAT initiation and included: (i) all-cause mortality; and (ii) breakthrough candidaemia, defined as the diagnosis of candidaemia in a patient who had received a systemic antifungal agent for at least 3 days. 9 
Ethics
The study was approved by the Ethics Committee of Sant'Orsola-Malpighi Hospital, reference number 222/2016/O/Sper; informed consent was obtained.
Microbiological studies
BCs (each set comprising a BACTEC Plus Aerobic/F culture vial and a BACTEC Lytic/10 Anaerobic/F culture vial) were incubated in a BACTEC FX instrument (Becton Dickinson, USA). For negative BC the standard maximum incubation period was 5 days. Each positive BC was smeared for Gram staining and subcultured on solid medium with short incubation time (1.5-3 h) for subsequent MALDI-TOF MS identification (VITEK-MS, bioMérieux, France). Gram staining and MALDI-TOF MS results were computationally notified to clinicians; yeast observation was immediately notified to IDCs by telephone call. Antimicrobial susceptibility tests were performed using VITEK 2 for Gram-negative bacteria and yeasts and the Microscan system for Grampositive bacteria (Beckman Coulter, USA). Antimicrobial susceptibility test results were computationally released.
A T2Candida test was performed using a 3 mL whole blood sample collected in a K2 EDTA Vacutainer tube (Becton Dickinson, USA). In the laboratory, specimens were immediately loaded on the T2Dx Instrument (T2 Biosystems) using the T2Candida panel following the manufacturer's protocol. After 3 h, results were displayed as negative, invalid or positive for three species groups: albicans/tropicalis, glabrata/krusei and parapsilosis. Invalid results were reported when the internal control was invalid and there were no positive T2MR signals.
Statistical analysis
Clinical sensitivity of T2Candida was derived from a 2%2 paired contingency table using positive BCs as the reference (Table S1 , available as Supplementary data at JAC Online). T2Candida and BCs were positive if they detected a Candida species that was identified in the corresponding BCs. Time to positive or negative results from the index BCs was compared using the Wilcoxon rank sum test.
Results
We included 46 out of 50 screened patients; 4 patients were excluded because BC and T2Candida samples were collected more than 12 h apart. The median time between BC and T2Candida sample collection was 5.1 h (IQR 2-15 h).
General characteristics of patients and risk factors for candidaemia are shown in Table 1 . All patients received an echinocandin as EAT and the median duration of EAT was 7 days (IQR 4-13 days). All-cause 90 day mortality was 37%; there were no cases of breakthrough candidaemia.
BCs were negative in 31 (67.4%) patients and positive in 15 (32.6%) patients. Distribution of isolates was as follows: Klebsiella pneumoniae (n " 4), Staphylococcus epidermidis T2Candida use in real life JAC (n " 4, but only one was a true bacteraemia), Escherichia coli (n " 3), Pseudomonas aeruginosa (n " 2), Enterococcus raffinosus (n " 2), Enterobacter cloacae (n " 1) and C. albicans (n " 1). Two patients had polymicrobial bacteraemia: one with E. coli and P. aeruginosa, the other with P. aeruginosa and E. raffinosus. T2Candida was negative, invalid and positive in 37, 5 and 4 patients, respectively. Three of the five samples with invalid results were retested and invalid results were obtained once again. The other two samples were not reprocessed because of the low amount of remaining blood. T2Candida was positive for parapsilosis and albicans/tropicalis in three patients and one patient, respectively; the albicans/tropicalis result was obtained in the patient with C. albicans bloodstream infection. Two of the three patients with discordant T2!(parapsilosis)/BC# results were on antifungal prophylaxis at the time of enrolment. All of them had a central venous catheter that was removed on the day of EAT initiation. EAT was continued for 12 days in two patients and 6 days in one patient. None of them died or experienced breakthrough candidaemia within 90 days (see Table S2 ).
Median times to results of microbiological tests are shown in Figure 1 . As shown in Figure 1(b) , T2Candida reduced time to a negative result by 5 days. With disease prevalence of 2.2% (95% CI " 0.07%-13.8%), T2Candida performance was: sensitivity " 100% (95% CI " 2.5%-100%), specificity " 91.8% (95% CI " 78%-98%), area under the curve " 0.96 (95% CI " 0.84-1.00), positive predictive value " 25% (95% CI " 0.63%-80.6%) and negative predictive value (NPV) " 100% (95% CI " 89.7%-100%).
Discussion
In this pilot study, we estimated the clinical performance of T2Candida in patients with multiple risk factors for candidaemia and severe sepsis or septic shock, showing that in this setting T2Candida has a very high NPV allowing potential reduction of the duration of EAT by 5 days.
T2Candida and BC results were concordant in all patients but three, where T2Candida was positive and BCs were negative. This kind of discordance (T2!/BC#) has been previously reported, mostly in patients receiving antifungal therapy. 15 Indeed, two of our patients were on antifungal prophylaxis at the time of enrolment. According to our and prior findings, T2Candida is likely to diagnose some cases of candidaemia that would be missed by cultures during prophylaxis or preemptive treatment. However, further studies are needed to define the biological significance of T2!/ BC# results, mainly in patients not receiving antifungal therapy.
We obtained 10.8% invalid results, a figure similar to that observed in the DIRECT and DIRECT2 trials where frozen samples were analysed. 11, 15 This is the first report about invalid results using freshly collected samples in clinical practice. Invalid results may stem from the presence of inhibitors in whole blood samples. 16 Only one of our patients with invalid results was receiving antifungal prophylaxis. We also observed that T2Candida performance was influenced by the deterioration of the cartridge before the expiration date and by mechanical problems with the instrument. The frequency and impact of T2Candida invalid results on clinical management should be further assessed.
Our study has several limitations. Single-centre design and small sample size may limit generalizability of our results. Although we selected patients with several risk factors for candidaemia and with high clinical severity, the prevalence of candidaemia was low (2.2%). This is a common problem in the assessment of new diagnostics in hospital epidemiology, which requires large sample sizes so that the CI around sensitivity can be precisely estimated. 17 On the other hand, such large sample sizes may not be realistic in terms of time and costs. 18 For example, if we wanted to estimate the sensitivity of T2Candida in our institution with less than 5% error and 90% power, we would have required 126 positive tests or 4846 high-risk patients to be screened. Alternative approaches, such as finding known positive patients identified by clinical cultures and then testing the new assay to determine sensitivity (i.e. 'cherry-picking' method), potentially introduce even larger biases and do not reflect 'real-world' test application. Other issues are that: (i) the sensitivity of BC to detect invasive Candida infection is poor-PCR could have been more appropriate as comparator, but its use is hampered by the lack of standardization; Giannella et al.
(ii) the risk factors used may not be appropriate to identify patients with candidaemia, but we selected them according to prior literature and local epidemiology; and (iii) T2Candida samples were obtained a median of 5.1 h (IQR 2-15 h) after drawing BC and EAT onset, which could have affected the amount of fungal cells or circulating DNA.
In conclusion, T2Candida may improve the management of candidaemia by shortening times to detection and species identification compared with BCs. Since it has high NPV, T2Candida could be helpful for antifungal stewardship purposes if further studies show that antifungal therapy can be safely withdrawn according to T2Candida negative results.
